Шизофрения - [53]
IQ and community care: C. Kelly et al., «Nithsdale Schizophrenia Surveys 20 — cognitive function in a catchment-area-based population of patients with schizophrenia», British Journal of Psychiatry (2000), 177: 348-53.
IQ and drugs: S. Mohamed et al., «Generalized cognitive deficits in schizophrenia — a study of first-episode patients». Archives of General Psychiatry (1999), 56(8): 749-54.
The core cognitive impairment in schizophrenia: B. Elvevag and T. E. Goldberg, «Cognitive impairment in schizophrenia is the core of the disorder». Critical Reviews in Neurobiology (2000), 14(1): 1-21.
Motivation in schizophrenia: S. G. Heilman et al., «Monetary reinforcement and Wisconsin Card Sorting performance in schizophrenia: why show me the money?», Schizophrenia Research (1998), 34(1–2): 67–75.
Single case approach: T. Shallice, P. W. Burgess, and C. D. Frith, «Can the neuropsychological case-study approach be applied to schizophrenia?». Psychological Medicine (1991), 21: 661-73.
Classifying symptoms: T. J. Crow, «Molecular pathology of schizophrenia: more than one disease process?», British Medical Journal (1980), 280(6207): 66-8.
Intellectual functioning and symptoms: E. C. Johnstone and C. D. Frith, «Validation of three dimensions of schizophrenic symptoms in a large unselected sample of patients». Psychological Medicine (1996), 26(4): 669-79.
Genius and madness: N. C. Andreasen, «Creativity and mental illness: prevalence rates in writers and their first-degree relatives». The American Journal of Psychiatry (1987), 144(10): 1.288-92; A. M. Ludwig, «Creative achievement and psychopathology: comparison among professions», American Journal of Psychotherapy (1992), 46(3): 330-56.
Superior abilities in the relatives of patients with schizophrenia: J. L. Karlsson, «Mental abilities of male relatives of psychotic patients», Acta Psychiatrica Scandinavica (2001), 104(6): 466-8.
Глава 4
Amphetamine psychosis: P. H. Connell, Amphetamine Psychosis (Maudsley Monographs, 1958); S. Tatetsu, «Metamphetamine psychosis», in Current Concepts of Amphetamine Abuse, ed. E. H. Elinwood (Rockville NIMH, 1972).
Experimental studies of amphetamine: J. D. Griffith, J. H. Cavanaugh, J. Held, et al., «Experimental psychosis induced by the administration of d-amphetamine», in Amphetamine and Related Compounds, ed. E. Costa and S. Garattini (Raven Press, 1970), pp. 897–904;
В. M. Angrist and S. Gershon, «The phenomenology of experimentally induced amphetamine psychosis: Preliminary observations». Biological Psychiatry (1970), 2: 95-107.
Amphetamine and dopamine: L. Kokkinidis and H. Anisman, «Amphetamine psychosis and schizophrenia — a dual model», Neuroscience and Biobehavioral Reviews (1981), 5 (4): 449-61.
Cannabis and schizophrenia: S. Andreasson, A. Engstrom, P. Allebeck, and U. Rydberg, «Cannabis and schizophrenia — a longitudinal study of Swedish conscripts». Lancet (1987), 2 (8574): 1483-6; W. Hall and L. Degenhardt, «Cannabis use and psychosis: a review of clinical and epidemiological evidence», Australian and New Zealand Journal of Psychiatry (2000), 34 (1): 26–34.
The cannabis receptor: M. Glass, «The role of cannabinoids in neurodegenerative diseases». Progress in Neuro-Psychopharmacology and Biological Psychiatry (2001), 25 (4): 743-65.
PCP and schizophrenia: D. C. Javitt and S. R. Zukin, «Recent advances in the phencyclidine model of schizophrenia», American Journal of Psychiatry (1991), 148 (10): 1301-8.
Discovery of antipsychotic drugs: J. Delay and P. Deniker, «Le traitement des psychoses par une méthode neurolyptique dérivée de l'hibernothérapie», in Congres de Médicins Aliénistes et Neurologistes de France, ed. P. Cossa (Maisson Editeurs Libraires de I’Académie de Médicine, Paris, 1952), pp. 497–502.
Efficacy of antipsychotic drugs: J. M. Davis and D. L. Gerver, «Neuroleptics — clinical use in psychiatry», in Handbook of Psychopharmacology Vol 10. Neuroleptics and Schizophrenia, ed. L. L. Iversen and S. D. Iversen (Plenum Press, 1978).
Dopamine and Parkinson's disease: 0. Hornykiewicz, «Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA)», British Medical Bulletin (1973), 29: 172-8.
The dopamine theory of schizophrenia: A. Carlsson and M. Lindquist, «Effect of chlorpromazine and haloperidol of formation of 3-methoxytyramine and normetanephrine in mouse brain», Acta Pharmacol. Toxicol. (1963): 140-4.
Dopamine blockade and the efficacy of antipsychotic drugs: P. Seeman et al., «Antipsychotic drug doses and neuroleptic/dopamine receptors». Nature (1976), 261: 717-9.
Atypical antipsychotics: J. Kane, G. Honigfeld, J. Singer, and H. Meltzer, «Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine». Archives of General Psychiatry (1988), 45: 789-96.
A revised dopamine theory of schizophrenia: S. Kapur and G. Remington, «Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient»,
